IDH2 and neoplasm: Analysis of the TMB revealed HMP in two patients with IDH-mutant gliomas at the time of disease recurrence, each carrying P/LP germline variants in MUTYH and ERCC6, respectively and in one patient with de novo IDH-wildtype tumor (NCI0392) carrying a pathogenic variant in MSH2.